FLT3 — Targeted Therapies, Trials & Pipeline

FLT3-ITD and TKD mutations are adverse-risk drivers in AML, now targeted by FLT3 inhibitors.

Approved drugs targeting FLT3

Investigational pipeline agents

Landmark trials